Ritonavir (CAS: 155213-67-5)

C₃₇H₄₈N₆O₅S₂

• HIV-1 and HIV-2 protease inhibitor.
• Glucose transporter 1 (GLUT1) and 4 (GLUT4) inhibitor. Inhibits transport of glucose across the plasma membranes of mammalian cells and consequently decreases glycolysis.
• Useful agent for immunometabolism research.
• Antitumor agent. Apoptosis inducer and cell proliferation inhibitor in GLUT1/GLUT4 overexpressed cancer cell lines.
• Tumor cells rely on elevated glucose consumption and metabolism for survival and proliferation. Glucose transporters mediating glucose entry are key proximal rate-limiting checkpoints. Among the fourteen SLC2A family members, GLUTs 1 and 4 are high-affinity glucose transporters.

1. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans: D.J. Kempf, et al.; PNAS 92, 2484 (1995)
2. Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy: D.J. Kempf, et al.; J. Med. Chem. 41, 602 (1998)
3. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients: R.K. Zeldin, et al.; J. Antimicrob. Chemother. 53, 4 (2004)
4. HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of GLUTs with differing affinities for GLUT1 and GLUT4: R.C. Hresko & P.W. Hruz; PLoS One 6, e25237 (2011)
5. Targeting Glycolysis and Compensatory Mitochondrial Metabolism In An In Vivo Xenograft Model Of Multiple Myeloma With FDA Approved Ritonavir and Metformin: S. Dalva-Aydemir, et al.; Blood 122, 1922 (2013)
6. Glucose transporter 1-mediated glucose uptake is limiting for B-cell acute lymphoblastic leukemia anabolic metabolism and resistance to apoptosis: T. Liu, et al.; Cell Death Dis. 5, e1470 (2014)
7. In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy: R.K. Mishra, et al.; J. Biol. Chem. 290, 14441 (2015)
8. A guide to immunometabolism for immunologists: L.A. O'Neill, et al.; Nat. Rev. Immunol. 16, 553 (2016)
9. Development of GLUT4-selective antagonists for multiple myeloma therapy: C. Wei, et al.; Eur. J. Med. Chem. 139, 573 (2017)